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Abstract: Placental insufficiency, high altitude pregnancies, maternal obesity/diabetes, maternal
undernutrition and stress can result in a poor setting for growth of the developing fetus. These adverse
intrauterine environments result in physiological changes to the developing heart that impact how
the heart will function in postnatal life. The intrauterine environment plays a key role in the complex
interplay between genes and the epigenetic mechanisms that regulate their expression. In this review
we describe how an adverse intrauterine environment can influence the expression of miRNAs
(a sub-set of non-coding RNAs) and how these changes may impact heart development. Potential
consequences of altered miRNA expression in the fetal heart include; Hypoxia inducible factor (HIF)
activation, dysregulation of angiogenesis, mitochondrial abnormalities and altered glucose and fatty
acid transport/metabolism. It is important to understand how miRNAs are altered in these adverse
environments to identify key pathways that can be targeted using miRNA mimics or inhibitors to
condition an improved developmental response.
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1. Introduction
Cardiovascular and metabolic disorders often present in adult life, but may have their origins
in changes to the intrauterine environment during fetal development [1,2]. Given that the number
of cardiomyocytes a human will have for life is set at birth, it is important to understand how
cardiomyocyte endowment is regulated in the developing fetus. The importance of miRNA expression
in cardiac development has been recognised, but how an adverse intrauterine environment can disrupt
miRNA expression in the fetal heart and subsequently alter the critical process of heart development
has not yet been explored. The prevalence of intrauterine growth restriction (IUGR) is as high as 10%
worldwide [3] and the number of women of reproductive age who are classified as overweight/obese
has increased to as many as 1 in 5 in pregnancy [4,5]. Therefore, it is important to determine the impact
that these adverse fetal conditions have on cardiac health in adulthood. Herein we highlight a number
of changes to the maternal and intrauterine environment and how these may impact on the expression
of fetal cardiac miRNAs during development.
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2. Developmental Programming in Early Life and Heart Disease
There were ~17.3 million deaths from cardiovascular disease in 2013, making it one of the
leading causes of death globally [6–8]. Cardiovascular disease in adults is generally attributed to
an unhealthy lifestyle with a focus on poor diet and smoking, interacting to a weak extent with
genetic susceptibility [9,10]. However, emerging evidence suggests that cardiovascular and metabolic
disorders in adult life can be initiated by physiological insults during fetal development (Figure 1) [1,2].
The associations between impaired development in utero and cardiovascular disease later in life
can be explained by the concept of the developmental origins of health and disease (DOHaD) [11].
The DOHaD hypothesis is defined as the “setting” of a physiological system by an early stimulus or
insult, during a critical period of development, when the manipulation of the environment, including
oxygenation and nutritional factors, can have long-lasting, or programmed, consequences for the
physiology of the fetus [1,11,12]. These insults can include placental insufficiency, living at high
altitude, maternal obesity, diabetes, maternal undernutrition and stress, each of which can impact on
the fetal intrauterine environment through changes in fetal oxygenation, nutrition and the hormonal
environment. The DOHaD hypothesis may help explain how changes in utero can result in altered
epigenetic regulation of cardiomyocyte endowment after an environmental insult and how this is
subsequently linked to programming of cardiovascular disease in adult life.
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3. Dysregulation of the Epigenome during Fetal Development
Epigenetic mechanisms involving mitotically heritable changes in gene expression without
changes to the DNA sequence can regulate fetal development and fetal programming during
pregnancy [13]. The control of fetal programming is mediated by at least three epigenetic pathways;
(i) DNA methylation, [14]; (ii) histone modifications that change how DNA is packaged with histone
proteins to form chromatin and (iii) the expression of non-coding RNAs including miRNAs and
long noncoding RNAs (lncRNAs; Figure 2) [13,14]. Specific miRNAs regulate the expression of
genes encoding epigenetic modifier enzymes while some lncRNAs bind to specific DNA sites and
provide scaffolds for binding of epigenetic modifier enzymes [15]. Epigenetic processes are tightly
regulated during embryonic and fetal growth and have important roles in the normal development
of organs, including the heart. Interactions between these epigenetic processes create the unique
gene expression programs that orchestrate the development of each tissue and this is particularly
important in cardiac development as many of these processes impact on metabolism. However, the
epigenome is vulnerable to dysregulation throughout life by environmental factors; with development
and embryogenesis being the most vulnerable periods [16]. Changes in the intrauterine environment
can cause epigenetic dysregulation, which is termed “environmental epigenomics” [16]. This reflects
the continuous interaction between the epigenome and the environment, including both endogenous
(e.g., hormone levels or immune response) and exogenous factors (e.g., oxygenation, nutritional and
drug exposures) [17]. The interplay between early life environmental epigenomics and development
may lead to altered tissue function later in life. It is therefore likely that changes in the intrauterine
environment, such as hypoxemia and dysregulation of maternal nutrient intake will impact upon the
epigenome during pregnancy potentially generating lifelong consequences. This review will focus
on fetal cardiac miRNA expression in the context of several adverse maternal conditions including;
maternal or fetal hypoxia, obesity, undernutrition and stress, and the potential negative postnatal
physiological outcomes.
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Figure 2. Epigenetic mechanisms. Epigenetic regulation can occur through several different pathways.
These include DNA ethylation, histone modification and non-coding RNAs. Non-coding RNAs such
as miRNAs and lncRNAs a e capable of modulating gene expressio through suppression of mRNA
expression or by direct regulation of epigenetic modifying enzymes.
4. miRNA Ex ression is Essential for the Regulation of Cellular Function in the Heart
Epigenetics is involved in the control of fetal heart development via multiple pathways such as
covalent modifications of DNA and histone proteins, as well as miRNA expression, which acts to
repress gene expression by interfering with mRNA translation or stability. DNA methylation and
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histone modification not only regulate the expression of protein-encoding genes, but also miRNAs [18].
Conversely, a subset of miRNAs control the expression of other epigenetic regulators including DNA
methyltransferases, histone deacetylases and polycomb group genes [18]. This feedback network
between miRNAs and other epigenetic pathways forms an “epigenetics–miRNA regulatory circuit”
that organizes the whole gene expression profile [18]. The human heart encodes over 700 miRNAs [19],
which modulate the expression of more than 30% of the protein encoding genes [20]. These miRNAs
are widely conserved across eukaryotes, and play an essential role in almost all aspects of cardiac
development and postnatal heart function [21]. miRNA precursors are expressed in the nucleus
(Figure 3) and this expression is often controlled in a cell type specific manner via transcription
factors [22]. The miRNA profile of each organ, including the heart, is therefore unique. miRNA
precursor transcripts are processed in the nucleus and cytoplasm (Figure 3) before the functional
~22 nucleotide miRNAs are formed. The mature miRNA then binds to the Argonaute protein to direct
the RNA-induced silencing complex (Figure 3; RISC; also referred to as miRNA-ribonucleoprotein
complex) to the target mRNA [22]. The miRISC complex regulates gene expression by translational
repression or RISC-mediated cleavage of the mRNA. Many miRNAs are highly conserved between
species and often retain the same mRNA targets. Since the human genome expresses a large variety
of different miRNAs in heart tissue, and bioinformatics algorithms predict that each miRNA has
hundreds of target transcripts, intricate regulation of essential cardiac developmental pathways is
therefore possible [23].
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Figure 3. Processing of miRNAs: (1) miRNAs are transcribed as 5′-capped large polyadenylated
precursor transcripts (pri-miRNA) primarily in a Polymerase II-dependent manner. Approximately
40% of human miRNAs are co-transcribed as clusters encoding up to eight distinct miRNA sequences
in a single pri-miRNA transcript; (2) Pri-miRNAs are cleaved within the nucleus by the microprocessor
complex containing Drosha (an RNaseIII-type nuclease) and a protein co-factor, DiGeorge syndrome
critical region 8 gene (DGC 8) in humans; (3) Th resulting 60–70 nucleotide hairpin structure
(pre-miRNA) encodes for a single miRNA sequence that is exported from the nu us to the cytoplasm
by Exportin-5; (4) Cytoplasmic pre-miRNAs re further cleaved by another RNaseIII-nuclease, Dicer,
in concert with cofactors (TRBP and PACT in hu ans), to eliminate the pre-miRNA loop sequence
forming a short-lived asymmetric duplex intermediate (miRNA: miRNA*); (5) The mature miRNA is
then loaded into the miRISC complex with Argonaute proteins; (6) miRNA guided suppression of the
target mRNA. Identification of the target mRNA is assisted by the “seed sequence”, which is essential
for the binding of the miRNA to the mRNA. The seed sequence is a conserved heptametrical sequence
that is typically situated at positions 2–7 from the miRNA 5′-end. Even if the base pairing of miRNA
with its target mRNA does not match perfectly, the “seed sequence” has to be perfectly complementary.
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Although the exact role of miRNAs in the epigenetic regulation of cardiac development has not
been fully elucidated, the importance of these non-coding RNAs has been evaluated by manipulating
the enzymes required to form the mature miRNA. Dicer, the enzyme required to process pre-miRNAs
into functional miRNA, is encoded for by a single gene Dicer1. Mutations in the Dicer1 gene are
embryonically lethal at a gestational age of 7.5 days in rodents [24] and lead to generalized growth
arrest in zebrafish embryos, which rarely survive beyond 13–14 days post-fertilization [25]. Due to the
lethality of global Dicer1 silencing, tissue specific deletion methods have helped determine the role
of this enzyme in cardiac development. Conditional knockout models utilising Cre-recombinase in
cardiac progenitor cells exhibit lethality or a poorly developed myocardium, indicating that cardiac
specific Dicer1 expression is essential in the morphogenesis and development of the fetal heart [26,27].
Dicer activity is also required for the maintenance of postnatal cardiac function, as demonstrated by
cardiomyocyte-specific Dicer1 ablation, which results in reduced mature miRNA in neonatal mouse
heart and associated dilative cardiomyopathy and heart failure by postnatal day 4 [28]. Furthermore,
Cre mediated cardiac deletion of Dicer1 leads to spontaneous cardiac remodelling in three week old
mice, resulting in increased rates of sudden death or a significant reduction in cardiac function by the
end of week 4 [29]. Dicer1 deletion in adult mice also results in cardiac remodeling. However, unlike
their younger counterparts, adult mice do not display premature sudden death. Instead Dicer1 deletion
in adulthood results in severe histopathological changes including pathological hypertrophy, extensive
inflammation and interstitial fibrosis [29]. Dicer1 deletion therefore demonstrates the integral role of
miRNAs in the regulation of cardiac development as well as postnatal maintenance of heart function.
Some of the most highly expressed miRNAs in the developing heart; miR-1 and miR-133a, have
served as excellent examples of the regulatory requirement for miRNAs during heart development.
In vivo studies have demonstrated the requirement for each of these miRNAs, with targeted deletion
and knockdown resulting in either embryonic lethality, pericardial edema, ventricular septal defects or
chamber dilatation in mouse models [30]. In addition to animal studies, several congenital cardiac
defects have been associated with altered expression of specific miRNAs. Within the hearts of patients
of the most common genetic disorder that leads to cardiac abnormalities, trisomy 21 (Down Syndrome),
five miRNAs were found to be overexpressed (miR-99a, let-7c, miR-125b-2, miR-155 and miR-802),
all of which are present on chromosome 21 [31]. Children with non-syndromic tetralogy of fallot
have 61 miRNAs significantly changed in their myocardium compared to normally developing
subjects [32]. Lastly, in the congenital heart condition of single ventricle malformation; 38 miRNAs
were downregulated and 10 upregulated compared to normal control cardiac tissue, with WNT and
mTOR signaling pathways as the most significantly affected by these changes [33]. These animal model
and clinical studies provide a strong basis for the fundamental requirement of miRNA expression
during fetal development, as well as demonstrate the consequences to their dysregulation in utero.
5. Chronic Hypoxemia Alters Heart Development and Changes the Expression of
Cardiac miRNAs
Although fetal hearts have a remarkable ability to grow, function and survive in a low oxygen
environment, chronic hypoxemia is associated with many cardiac related complications, and can
cause both short and long term effects [34]. Chronic hypoxemia during fetal development can
significantly delay heart growth and this is of particular importance in high altitude pregnancies, with
~140 million people living at high altitude worldwide [35]. Pregnant women living at high altitude
have lower PaO2 (50 mm Hg) and thus there is altered placental growth compared to a pregnancy
at sea level (PaO2, 95 mm Hg) [36,37]. These pregnancies are also at an increased risk of developing
IUGR (birth weight < 10th centile for gestational age) and/or delivering a low birth weight (LBW;
birth weight < 2.5 kg) infant, which has been related to increased infant mortality, premature birth,
and development of cardiovascular related diseases in adulthood [38,39]. Chronic hypoxemia in utero
is not limited to high altitude pregnancies, with additional causes that can include: umbilical cord
compression, placental insufficiency resulting from aberrant placental development, pre-eclampsia,
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smoking, pollution and hemoglobinopathy [40]. LBW associated with reduced fetal growth is at least
twice as common in developing countries, and reflects poor maternal nutrition, although maternal
smoking is an important risk factor [40]. These factors contribute to reduced oxygen delivery and
in some cases nutrients, to fetal tissues, which induces chronic hypoxemia in utero, resulting in
adaptations to fetal development due to environmental stress.
The adverse conditions created by chronic hypoxemia in utero are particularly disruptive to
the development of cardiac tissue, due to its high metabolic demand [34]. Insufficient oxygen
in utero results in myocardial thinning and ventricle dilation in addition to epicardium detachment
in fetal rat hearts [41]. Similarly, hypoxemia delayed fetal heart maturation, when compared to
controls in both chickens and mice [41,42], with either myocardial hypoplasia or cardiomyocyte
hypertrophy in other animal models including sheep, as well as in humans [34,41,43–47]. The increased
size of cardiomyocytes postnatally is likely to be compensatory for the reduced total number of
cardiomyocytes [3,48,49] and reinforced by the increased heart to body weight ratio when exposed
to prenatal hypoxemia [43,44,47]; suggesting either reduced growth of other non-essential organs
in favour of heart development or cardiac enlargement. This decrease in cardiomyocyte number in
hypoxemic fetuses is likely influenced via increased programmed cell death and autophagy during
critical windows of heart development [48]. Hypoxia mediated apoptosis is controlled by increased
cell death signalling through elevated caspase 3 activity and Fas activation, and suppressed by cell
survival pathways, as indicated by Bcl-2 and Hsp70 expression in fetal hearts [44]. The reduction
of proliferation is a result of premature exit from the cell cycle, as seen by the higher percentage of
terminally differentiated cardiomyocytes in the heart at birth [44,50–53]. Prolonged insufficient oxygen
supply can therefore cause abnormal fetal heart structural development, due to reduced cardiomyocyte
proliferation and increased apoptosis and autophagy.
The mechanisms underpinning the changes in gene expression and function of hypoxemic fetal
hearts are complex and not completely understood, however, it is likely that miRNA expression
plays a key role. The chief regulator of oxygen homeostasis in the hypoxemic heart are the
hypoxia inducible factors (HIFs), which mediate the expression of genes with hypoxia response
elements [48]. During acute hypoxia, HIFs recruit mechanisms to increase oxygen supply (angiogenesis,
erythropoiesis and vasodilation) and decrease oxygen demand (decreased oxidative metabolism and
increased glycolysis), as well as regulating the cell cycle, apoptosis and autophagy [48,54]. Although the
mechanisms underpinning HIF stabilization in hypoxemia are well understood, many mechanisms
involved in the regulation of its expression remain unclear. miRNAs have been implicated in the
regulation of HIFs, with microarray analysis revealing several hypoxia-inducible miRNAs. Among
these are miR-155, miR-138, miR-26, miR-22, miR-34a, miR-214, miR-199a, miR-696, miR-484, and
miR-210 (Figure 4), which target HIFs, or have confirmed hypoxia response elements (HRE) in their
promoter regions, implicating them in a network of miRNAs that may regulate or are regulated by
HIFs [55–67]. Vascular endothelial growth factor (VEGF) also has a HRE and is a positive regulator
of angiogenesis, as well as a pivotal growth factor in fetal development and is regulated by many
factors [68], but the role of miRNAs in its regulation is not clear. Some miRNAs that have predicted
targets to angiogenic factors are sharply down-regulated after hypoxia treatment in cell culture,
including miR-15b, miR-16, miR-20a and miR-20b [69], suggesting that they are involved in VEGF
regulation. Chronic hypoxemia can therefore alter the amount of myocyte proliferation, apoptosis and
hypertrophy that occurs in the fetal heart [48], but the exact role of miRNA expression in this process
is yet to be fully elucidated.
Interestingly, a specific set of miRNAs are expressed almost exclusively in the placenta and
secreted into the fetal circulation via exosomes [70–72]. These circulating miRNAs act in a similar
mechanism to hormones, and can be detected in both the maternal and fetal compartments, including
the fetal heart [72]. The expression of miRNAs was shown to be disrupted in placental tissue from
small for gestational age pregnancies and placental pathologies such as IUGR [73,74] as well as
mothers exposed to environmental pollutants [75]. The role of these placental specific miRNAs in heart
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development have yet to be fully explored, but there is some evidence that altered maternal nutrition
as well as placental pathologies such as placental ablation, umbilical cord compression, and placental
insufficiency alter circulating miRNA expression and this may impact fetal heart development.Int. J. Mol. Sci. 2017, 18, 2628 7 of 19 
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Low birth weight and undernutrition have been associated with increased risk of chronic heart
disease in adult life [83–85]. This could possibly be linked to epigenetic adaptations that have occurred
in utero to ensure survival of the fetus, but lead to adverse health outcomes in adulthood. Nutrition may
be the largest non-genetic influence in fetal development, including factors such as maternal body
composition, diet, and the efficiency of nutrient transport to the fetus [86]. The fetal heart is sensitive
to changes in glucose availability as glucose oxidation is the main source of energy in the developing
heart [87]. Throughout pregnancy there is a dominance of glucose transporter 1 (GLUT1) in cardiac
tissue, however its expression can be modulated by maternal diet. In cell culture, GLUT1 mRNA is
down-regulated as a result of reduced nutrients, and this transcript has been identified as a target of
several miRNAs such as miR-130b, miR-19a, miR-19b and miR-301a [88]. Conversely, when GLUT1 is
up-regulated as seen in cell culture models of maternal diabetes and maternal overnutrition, there is a
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correlation with decreased miR-199a, miR-138, miR-150 and miR-532-5p (Figure 5) [88]. After birth,
glucose transport in the heart is mostly achieved by glucose transporter 4 (GLUT4) [89] and regulated
by the insulin receptor (IR), insulin receptor substrate 1 (IRS-1) and PI3K, which in turn phosphorylates
phosphoinositide-dependent kinase-1 (PDPK-1) and/or Akt. The activation of these processes can
translocate GLUT4 to the plasma membrane to facilitate postnatal glucose uptake. GLUT4 expression
is regulated by miR-133 and miR-195-5p, both of which have been implicated in the inhibition of
cardiomyocyte proliferation (Figure 5) [90]. High glucose concentrations also increase the expression of
miR-1 and miR-206 in cardiomyocytes, which have been implicated in myocyte development [91] and
high levels of apoptosis in H9c2 cells [92]. The diabetic heart experiences a number of metabolic changes
characterized by insulin resistance, reduced cellular glucose import and oxidation, and increased
mitochondrial fatty acid import and oxidation. A number of miRNA have been identified to play a role
in regulating these metabolic changes including miR-216a, miR-199a, miR-195 and miR-34a [93,94].
In addition to metabolic changes, miRNAs may also play a role in diabetic cardiomyocyte apoptosis
and cell survival signaling [95]. miRNA expression in the fetal heart may be significantly modulated
by maternal nutrition and plasma glucose concentrations, and it is therefore important to identify the
key miRNAs and their target genes, which are affected by this process and how this may influence
cardiomyocyte endowment.
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Figure 5. Regulation of miRNA expression in response to altered glucose transport. miR-199a,
miR-138, miR-150, miR-532-5p, miR-130b, miR-19a, miR-19b and miR-301a have been implicated
in regulating GLUT1 expression; associated with left ventricular hypertrophy and heart failure [96,97].
miR-133 and 195-5p regulate GLUT4 expression, which has been associated with hypertrophy and
glucose homeostasis within the heart [98]. Expression of miR-1 and miR-206 are upregulated by
increased glucose concentrations and target HSP60 what has a role in glucose mediated apoptosis
in cardiomyocytes [99]. miR-216a regulates CAV2 expression, which plays a role in ischemic heart
failure [94]. miR-195 expression is dysregulated by diabetes and acts on SIRT1, involved in insulin
signaling and mitochondrial function [95]. HSP60; heat shock protein 60, GLUT1; glucose transporter 1,
GLUT4; glucose transporter 4 CAV2; caveolin 2, SIRT1; sirtuin 1. Pointed arrow represent downstream
effects, blocked arrows represent downregulation of target genes.
Shortly after birth there is a transition from mainly glucose metabolism to fatty acid oxidation
as a source of cardiac energy, and the programmed effects acquired during fetal development may
alter the expression of key postnatal factors in the regulation of fatty acid metabolism. Fatty acid
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oxidation in the heart is regulated by the phosphorylation of AMP-activated protein kinase (AMPK)
and acetyl CoA carboxykinase (ACC) [100–102]. Whereas β-oxidation in the heart is also regulated by
peroxisome proliferator activated receptor (PPARα; promotes uptake, utilization, and catabolism of
fatty acids [103]), carnitine palmitoyltransferase-1 (CPT1; facilitates the transport of fatty acids into
the mitochondria [104]), and pyruvate dehydrogenase kinase-4 (PDK-4; inhibits PDH, upregulating
fatty acid β-oxidation [105,106]). Cpt1α expression is controlled by miR-370, which in turn is regulated
by miR-122 (Figure 6) [107]. There are several other miRNAs associated with this pathway, including
miR-451, which has higher expression in glucose rich environments, controlling AMPK expression [108];
miR-22, which regulates PPARα [109]; and miR-107, which regulates PDK-4 expression (Figure 6) [110].
Altered maternal nutrition may prime the fetal heart for exposure to stress in the postnatal environment,
and it is therefore important to understand the underlying mechanisms that are regulated via
miRNA expression.
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PPARα has been associated with cardiac fibrosis, pathologic remodeling and cardiomyopathy during
development [111] and is a target of miR-22 in the heart. miR-122 regulates miR-370 which in
turn regulates CPT1 expression which has been associated with susceptibly to cardiotoxicity [112].
miR-451 mediates AMPK expression which is associated with apoptosis, hypertrophy and increased
susceptibility to ischemia [113]. PDK-4 expression has been associated with loss of metabolic flexibility
and exacerbation of cardiomyopathy [114] and is a predicted target of miR-107. PPARα; peroxisome
proliferator activated receptor, CPT1; carnitine palmitoyltransferase-1, AMPK; AMP-activated protein
kinase, PDK-4; pyruvate dehydrogenase kinase-4. Pointed arrow represent downstream effects, blocked
arrows represent downregulation of target genes.
7. Altered Cardiac miRNA Expression in Response to Maternal Disease and Stress
In addition to gestational diabetes (as discussed in Section 6), there are a number of diseases
prevalent in pregnant women what may alter fetal miRNA expression. Gestational hypertension effects
up to 8% of pregnancies and has been associated with a number of changes in miRNA expression in
peripheral blood, including highly expressed cardiac miRNAs; miR-1 and miR-133a, (Figure 7) and
have a strong correlation with severity of disease [115]. These circulating miRNAs can transfer across
the placenta to regulate fetal gene expression [116]. Maternal infections during pregnancy often pose
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a significant threat to the heath of the fetus. Individual viral, bacterial and parasitic infections have
specific sets of miRNAs associated with their physiological response [117,118]. Although the current
dogma is that the fetus is kept sterile from maternal bacterial infection, miRNAs that are altered in
response to maternal infection can transfer to the fetus, altering fetal gene expression. In addition,
viruses can also gain access to the placenta and fetus through a variety of means, including transmission
through trophoblasts, transfer of infected macrophages, invasive surgical procedures or vaginal
infection [119]. Maternal inflammation from allergy may also play a role in transfer of circulating
miRNAs to the fetus. Asthma for example has been associated with a specific subset of miRNAs in
biological fluids, including miR-629-3p, miR-223-3p, miR-142-3p, and miR-146a (Figure 7) [120,121].
Placental disorders remain as one of the largest impacts on fetal development, including
those found in ectopic pregnancies, placenta previa, intrauterine bleeding and placental abruption.
Previous studies have proven distinct dysregulation of placental miRNAs in response to these
disorders. For example, placenta previa and placental abruption have both been associated with
altered circulating concentrations of miR-517a and miR-517c (Figure 7) [122], pregnancy-associated,
placenta-specific miRNAs. As discussed above, these placentally expressed miRNAs are released
into the fetal circulation via exosomes and act somewhat like hormones, though the effect on cardiac
development has not yet been explored [70–72]. It is also important to note that these disorders may
also interrupt placental transfer of maternal miRNAs to the fetal tissues, impairing any exosomal
miRNA signaling that may be important to fetal development.
Maternal stress can be caused by a range of factors including psychological stress (e.g., grief,
anxiety and depression) and physical stress (e.g., shift work, undernutrition or environmental
mishaps) [123,124]. If sufficiently severe, these factors may alter the intrauterine environment,
pre-emptively priming the fetus for an anticipated stressful postnatal environment. Maternal stress
during pregnancy has been extensively studied in relation to the development of the fetal brain and
the hypothalamo–pituitary–adrenal (HPA) axis. These studies demonstrate changes in molecular and
behavioral differences in offspring of chronically stressed mothers [123,125–127]. The major stress
hormone, cortisol, increases in the maternal circulation two to four fold over the course of gestation.
Fetal exposure to the increasing concentrations of maternal cortisol is regulated by 11BHSD2 in the
placenta, which acts to convert active cortisol into the inactive form cortisone [127]. The expression
of 11BHSD2 in the placenta also increases across gestation, providing partial protection of the fetus
from maternal cortisol. However, the placental expression of this enzyme decreases towards the
end of pregnancy, allowing a large portion of maternal cortisol to reach the fetus. This normal
decrease in placental 11BHSD2 expression works in concert with the developing fetal adrenal gland
to ensure that the fetus has sufficient cortisol during the third trimester of pregnancy, when many
organs—especially the lungs—require this for complete maturation. Although the fetus is somewhat
protected from maternal cortisol for most of the time during gestation, in some situations where
cortisol is over-secreted or placental transport is impaired, excess levels of maternal cortisol can reach
the fetus.
Several miRNAs have been identified as regulators of steroid production and the stress
response. For example, miR-24 is a key regulator of CYP11B1 (11β-hydroxylase) and CYP11B2
(aldosterone synthase), responsible for the final stages of cortisol and aldosterone biosynthesis [128].
Several other miRNAs, including miR-29, miR-208, miR-499, miR-16, miR-20b, miR-126 and miR-144,
(Figure 7) have altered cardiac expression or circulating concentrations in response to stress [129–131].
High concentrations of cortisol during pregnancy can negatively impact on heart development with
evidence of hypertrophy in myocytes from the left ventricular free wall from fetal sheep and altered
glucose transport and angiotensin expression [132]. It is likely that miRNAs play a role in these
important changes. However, the expression of miRNAs in heart tissue under high cortisol stimulation
during fetal development is yet to be investigated in detail.
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8. Conclusions
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Dysregulation of miRNA pathways as result of hypoxia may contribute to hese nega ive outcomes.
Although currently the molecular pathways esulting in adverse outcomes have not been elucidat d
in overw ight, obese or diabetic pregnanc es, we h ve identified key pathways by w ich changes to
glucose metabolism may dysregulate the exp ssion of key miRNAs involved in developing a healthy
heart. Since there are thousands of miRNAs, each regulating multiple target ge es, this complex
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network of gene regulation will require further investigation to tease apart the impact of each altered
miRNA on their regulatory networks. Taken together, it is clear that changes in miRNA expression as
a result of altered intrauterine environment may contribute to negative cardiac outcomes as a result
of fetal hypoxemia, maternal overnutrition and maternal stress. Future research may identify key
miRNAs that can be targeted using mimics or inhibitors to condition an improved response in adverse
developmental conditions.
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